A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson?s disease (PDD) - ND A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exeloncapsu ...
A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson?s disease (PDD) - ND A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exeloncapsu ...
mild to moderately severe dementia associated with Parkinson?s disease (PDD) MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease mild to moderately severe dementia associated with Parkinson?s disease (PDD) MedDRA version: 9.1;Lev ...
Product Name: Exelonpathtransdermal Product Code: ENA713B INN or Proposed INN: Rivastigmine Trade Name: EXELON INN or Proposed INN: Rivastigmine Trade Name: EXELON INN or Proposed INN: Rivastigmine Trade Name: EXELON INN or Proposed INN: Rivastigmine Trade Name: EXELON INN or Proposed INN: Rivastigmine Product Name: Exelonpathtransdermal Product Code: ENA713B INN or Proposed INN: Rivastigmine Product Name: Exelonpathtransdermal Product Code: ENA713B INN or Proposed INN: Rivastigmine Trade Nam ...